Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanism of Action and Clinical Effect of BI 655130 (spesolimab) in Patients with Fistulizing Crohn's Disease
2017-003090-34Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of spesolimab in Crohn's disease, sponsored by Boehringer Ingelheim. Primary endpoint: Total number of deregulated genes at week 4. Started Oct 2018; status: completed.
02
Drugs
spesolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-003090-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003090-34.